Biogen Inc. (BIIB)

業務介紹

碧生源公司(Biogen Inc.)發現、開發、製造和提供治療神經和神經退行性疾病的療法。該公司提供TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI和FAMPYRA用於治療多發性硬化症(MS);SPINRAZA用於治療脊髓性肌萎縮症;以及FUMADERM用於治療斑塊性牛皮癬。它還提供BENEPALI(參考ENBREL的依那西普生物類似藥)、ADUHELM(用於治療阿爾茨海默病)、IMRALDI(參考HUMIRA的阿達木單抗生物類似藥)和FLIXABI(參考REMICADE的英夫利西單抗生物類似藥)。此外,該公司還提供RITUXAN(用於治療非霍奇金淋巴瘤、慢性淋巴細胞白血病(CLL)、類風濕性關節炎、兩種形式的ANCA相關血管炎和普通型天疱瘡)、RITUXAN HYCELA(用於非霍奇金淋巴瘤和CLL)、GAZYVA(用於治療CLL和濾泡性淋巴瘤)和OCREVUS(用於治療復發性MS和原發性進行性MS)以及其他抗CD20療法。此外,該公司正在開發BIIB135、BIIB061、BIIB091和BIIB107(用於治療MS和神經免疫學)、Aducanumab、Lecanemab、BIIB076和BIIB080(用於治療阿爾茨海默病和癡呆)、BIIB067、BIIB078、BIIB105、BIIB100和BIIB110(用於治療神經肌肉疾病)、BIIB124、BIIB094、BIIB118、BIIB101和BIIB122(用於治療帕金森氏病和運動障礙)、BIIB125和BIIB104(用於治療神經精神疾病)、Dapirolizumab pegol和BIIB059(用於治療免疫相關疾病)、BIIB093和BIIB131(用於治療急性神經病學)、BIIB074(用於治療神經病理性疼痛)以及BYOOVIZ、BIIB800和SB15生物類似藥(處於不同開發階段)。該公司與Acorda Therapeutics, Inc.、Alkermes Pharma Ireland Limited、Denali Therapeutics Inc.、Eisai Co., Ltd.、Genentech, Inc.、Neurimmune SubOne AG、Ionis Pharmaceuticals, Inc.、Samsung Bioepis Co., Ltd.、Sangamo Therapeutics, Inc.和Sage Therapeutics, Inc.有合作和許可協議。碧生源公司成立於1978年,總部位於麻薩諸塞州劍橋。



Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

公司網址

https://www.biogen.com